MNG731
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.257
- E2F_TARGETS+0.222
- G2M_CHECKPOINT+0.219
- ANGIOGENESIS+0.196
- SPERMATOGENESIS+0.192
- MTORC1_SIGNALING+0.126
- KRAS_SIGNALING_UP+0.121
- ANDROGEN_RESPONSE+0.072
- PROTEIN_SECRETION+0.058
- COMPLEMENT+0.040
Top 10 suppressed
- MYC_TARGETS_V2-0.481
- WNT_BETA_CATENIN_SIGNALING-0.427
- INTERFERON_ALPHA_RESPONSE-0.419
- TGF_BETA_SIGNALING-0.375
- INTERFERON_GAMMA_RESPONSE-0.366
- DNA_REPAIR-0.359
- UV_RESPONSE_UP-0.353
- APICAL_SURFACE-0.328
- HEDGEHOG_SIGNALING-0.311
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.308
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202429 | — | — | 0.831 |
| 2 | MNG79 | — | — | 0.766 |
| 3 | EPT0808 | EPN | Posterior Fossa EPN | 0.744 |
| 4 | MNG1185 | — | — | 0.743 |
| 5 | MNG84 | — | — | 0.738 |
| 6 | MNG370 | — | — | 0.732 |
| 7 | MNG159 | — | — | 0.730 |
| 8 | SRR10842347 | — | — | 0.726 |
| 9 | SRR10899998 | — | — | 0.722 |
| 10 | SRR627451 | GTEX | — | 0.720 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.257 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.222 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.219 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.196 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.192 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.126 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.121 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.072 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.058 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.040 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.023 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.009 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.009 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.002 | Temsirolimus | — uncovered |